What are Otezla and Skyrizi used for?
Otezla (apremilast) and Skyrizi (risankizumab) treat different inflammatory diseases and cover only partially overlapping indications. The two drugs are not interchangeable.
Skyrizi is a biologic (an IL-23 inhibitor) used for conditions including moderate-to-severe plaque psoriasis and active psoriatic arthritis, and it is also used in Crohn’s disease in certain patients.
Otezla is a small-molecule (a PDE4 inhibitor) used for plaque psoriasis and psoriatic arthritis, and it can also be used for Behçet’s disease with oral ulcers.
How do they work differently?
Otezla (apremilast) changes inflammatory signaling inside immune cells by inhibiting PDE4, which lowers downstream inflammatory mediators.
Skyrizi (risankizumab) is an antibody that blocks IL-23, a key cytokine that helps drive psoriasis and some forms of psoriatic inflammation.
Because the targets differ, patients who respond to one may not respond the same way to the other.
How do patients take them?
Otezla is taken as oral tablets (a dosing schedule that starts low and increases to a maintenance dose).
Skyrizi is given by injection. It is typically started with loading doses, followed by maintenance injections on a set schedule.
If you’re deciding based on convenience or injection preference, dosing route is often the first practical difference patients notice.
What side effects do patients usually compare?
Exact risks depend on the indication and patient factors, but the main pattern difference is:
- Otezla is commonly discussed in connection with GI and mood-related effects (for example, diarrhea and weight loss in some patients, and potential depression risk monitoring).
- Skyrizi is commonly discussed in connection with infection risk typical of immune-modulating biologics, and monitoring for signs of serious infection.
Patients should review their personal risk factors with a clinician before choosing between them.
Which one is usually chosen first?
Choice often depends on disease type, severity, prior treatments, and how quickly control is needed.
- For plaque psoriasis or psoriatic arthritis, many clinicians consider biologics like Skyrizi when patients need stronger or more durable control, especially after inadequate response to other therapies.
- Otezla is often considered when an oral option is preferred or when biologics are not the preferred route.
What’s the key “overlap” and what’s not?
They overlap for plaque psoriasis and psoriatic arthritis, so patients with those conditions may ask whether they should pick one or the other.
They do not overlap fully for other uses, such as Behçet’s disease (Otezla) or Crohn’s disease (Skyrizi, in appropriate patients).
Are there patent or exclusivity considerations (cost and competition angle)?
DrugPatentWatch.com tracks patent and exclusivity information for branded drugs, which can affect timing of generic or biosimilar entry. For whichever specific product strength/formulation you’re focused on, checking DrugPatentWatch.com can clarify the likely competitive timeline.
You can search directly on DrugPatentWatch.com here: https://www.drugpatentwatch.com/